Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can feeding ICU patients curb muscle breakdown? a new study investigates

NCT ID NCT07059988

Knowledge-focused Sponsor: Karolinska University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This study looks at how the body's production of glucose, fat, and protein changes in critically ill patients on ventilators when they receive nutrition. Researchers will measure these changes using special labeled tracers, comparing a fasting state to a fed state. The goal is to understand when the body's breakdown of energy stores becomes responsive to feeding, which could help improve nutritional care in the ICU.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Parenteral nutrition (intravenous feeding) and stable isotope tracers (labeled glucose, phenylalanine, glycerol)
What this could lead to
If successful, this could help tailor nutrition therapy for ICU patients, potentially improving recovery and reducing muscle wasting.
What could go wrong
This is a small, early-stage study (40 participants) focused on understanding metabolism, not a treatment trial. Results may not apply to all ICU patients, and the use of invasive monitoring limits generalizability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For the ICU group: 1. ≥18 years old and admitted to the ICU 2. Invasive mechanical ventilation 3. Arterial and central line in situ 4. Expected to remain in ICU \>72 hours For the control group: 1\. ≥18 years old Exclusion Criteria: 1. Lack of informed consent by patient/next of kin 2. Liver transplant 3. Acute or acute on chronic liver failure 4. Cirrhosis 5. Known diabetes mellitus 6. Pancreatic surgery 7. Acute or chronic pancreatitis 8. Pregnancy 9. Intubated only for airway protection or neurologic deficit 10. Mitochondrial disease 11. Disorder of amino acid metabolism 12. Familial hypertriglyceridemia 13. Severe acquired hypertriglyceridemia (≥10 mmol/L) 14. Requiring treatment of hypoglycemia in the last 72 hours before inclusion. 15. Requiring ongoing large volume resuscitation of crystalloids or blood products 16. \>72 hours in ICU before enrollment 17. Readmission to ICU within 1 week of ICU discharge. 18. Morbidly obese (BMI ≥35) 19. Limitations of treatment to best supportive care 20. Ongoing treatment with insulin/glucose related to hyperkalemia

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Critical illness are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Critical Illness nutritional disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Critical illness Metabolism and nutrition disorder

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Karolinska University Hospital Huddinge

    RECRUITING

    Stockholm, 14186, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.